Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus

Microbiol Spectr. 2023 Feb 14;11(1):e0243022. doi: 10.1128/spectrum.02430-22. Epub 2023 Jan 10.

Abstract

The rise of antibiotic resistance and dearth of novel antibiotics have posed a serious health crisis worldwide. In this study, we screened a combination of antibiotics and nonantibiotics providing a viable strategy to solve this issue by broadening the antimicrobial spectrum. We found that chenodeoxycholic acid (CDCA), a cholic acid derivative of the traditional Chinese medicine (TCM) Tanreqing (TRQ), synergizes with amikacin against Staphylococcus aureus in vitro, and this synergistic killing was effective against diverse methicillin-resistant S. aureus (MRSA) variants, including small-colony variants (SCVs), biofilm strains, and persisters. The CDCA-amikacin combination protects a mouse model from S. aureus infections. Mechanistically, CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates reactive oxygen species (ROS) generation by inhibiting superoxide dismutase activity. This work highlights the potential use of TCM components in treating S. aureus-associated infections and extend the use of aminoglycosides in eradicating Gram-positive pathogens. IMPORTANCE Multidrug resistance (MDR) is spreading globally with increasing speed. The search for new antibiotics is one of the key strategies in the fight against MDR. Antibiotic resistance breakers that may or may not have direct antibacterial action and can either be coadministered or conjugated with other antibiotics are being studied. To better expand the antibacterial spectrum of certain antibiotics, we identified one component from a traditional Chinese medicine, Tanreqing (TRQ), that increased the activity of aminoglycosides. We found that this so-called agent, chenodeoxycholic acid (CDCA), sensitizes Staphylococcus aureus to aminoglycoside killing and protects a mouse model from S. aureus infections. CDCA increases the uptake of aminoglycosides in a proton motive force-dependent manner by dissipating the chemical potential and potentiates ROS generation by inhibiting superoxide dismutase activity in S. aureus. Our work highlights the potential use of TCM or its effective components, such as CDCA, in treating antibiotic resistance-associated infections.

Keywords: Staphylococcus aureus; antibiotic resistance; chenodeoxycholic acid; dual mechanism; traditional Chinese medicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amikacin / pharmacology
  • Aminoglycosides / pharmacology
  • Aminoglycosides / therapeutic use
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus*
  • Mice
  • Microbial Sensitivity Tests
  • Reactive Oxygen Species
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus
  • Superoxide Dismutase / pharmacology
  • Superoxide Dismutase / therapeutic use

Substances

  • Amikacin
  • Reactive Oxygen Species
  • Anti-Bacterial Agents
  • Aminoglycosides
  • Superoxide Dismutase